shorted at $67, seems to be overbought
The infections from Roche’s Avastin have left many patients blind, while a study by John Hopkins University found that patients given Avastin to treat AMD were 11% more likely to die and 57% more likely to suffer a stroke than those treated with the more expensive Lucentis. With these problems in the market, a potential approval for EYLEA could help the drug into a very ready marketplace.
Investors interested in gaining exposure to this opportunity may want to consider at-the-money February 2012 calls trading with a premium of $11.30. With a breakeven point of $71.30, any more beyond this would have a cost basis of just $11.30 per share, making the upside potential very significant and the upfront capital requirements relatively modest.
http://seekingalpha.com/article/291187-3-analyst-healthcare-picks-ready-to-break-out?source=yahoo
Recent REGN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/06/2024 08:03:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 08:05:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 08:04:55 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 08:01:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 08:01:22 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/02/2024 02:43:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:18:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 08:02:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/01/2024 11:15:21 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 11:06:07 AM
- Regeneron Reports Second Quarter 2024 Financial and Operating Results • GlobeNewswire Inc. • 08/01/2024 10:30:00 AM
- Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation • GlobeNewswire Inc. • 07/31/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:00:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:00:30 AM
- Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD • GlobeNewswire Inc. • 07/03/2024 05:00:00 AM
- Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm • PR Newswire (US) • 07/02/2024 04:53:00 PM
- Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma • GlobeNewswire Inc. • 06/28/2024 11:00:00 AM
- Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2024 • GlobeNewswire Inc. • 06/27/2024 08:05:00 PM
- Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine • GlobeNewswire Inc. • 06/26/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 08:01:48 PM
- Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Treated Multiple Myeloma • GlobeNewswire Inc. • 06/16/2024 10:10:09 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/14/2024 08:26:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/13/2024 08:01:19 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/12/2024 09:04:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:10:49 PM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM
Fifty 1 Labs, Inc. and All-In-Extracts Announce Joint Venture to Develop and Release New Testosterone Boosting Supplement • BLEG • Aug 5, 2024 8:30 AM
Kona Gold Beverages, Inc. Announces Strategic Initiatives and Corporate Direction Changes • KGKG • Aug 2, 2024 2:00 PM
POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • POET • Aug 1, 2024 9:28 AM
Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM
VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM